Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 337 to 348 of 3217 entries
Sorted by: Best Match Show Resources per page
Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial.

Cancer cell

Pusztai L, Yau C, Wolf DM, Han HS, Du L, Wallace AM, String-Reasor E, Boughey JC, Chien AJ, Elias AD, Beckwith H, Nanda R, Albain KS, Clark AS, Kemmer K, Kalinsky K, Isaacs C, Thomas A, Shatsky R, Helsten TL, Forero-Torres A, Liu MC, Brown-Swigart L, Petricoin EF, Wulfkuhle JD, Asare SM, Wilson A, Singhrao R, Sit L, Hirst GL, Berry S, Sanil A, Asare AL, Matthews JB, Perlmutter J, Melisko M, Rugo HS, Schwab RB, Symmans WF, Yee D, Van't Veer LJ, Hylton NM, DeMichele AM, Berry DA, Esserman LJ.
PMID: 34143979
Cancer Cell. 2021 Jul 12;39(7):989-998.e5. doi: 10.1016/j.ccell.2021.05.009. Epub 2021 Jun 17.

The combination of PD-L1 inhibitor durvalumab and PARP inhibitor olaparib added to standard paclitaxel neoadjuvant chemotherapy (durvalumab/olaparib/paclitaxel [DOP]) was investigated in the phase II I-SPY2 trial of stage II/III HER2-negative breast cancer. Seventy-three participants were randomized to DOP and...

Cite
Pusztai L, Yau C, Wolf DM, et al. Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial. Cancer Cell. 2021;39(7):989-998.e5doi: 10.1016/j.ccell.2021.05.009.
Pusztai, L., Yau, C., Wolf, D. M., Han, H. S., Du, L., Wallace, A. M., String-Reasor, E., Boughey, J. C., Chien, A. J., Elias, A. D., Beckwith, H., Nanda, R., Albain, K. S., Clark, A. S., Kemmer, K., Kalinsky, K., Isaacs, C., Thomas, A., Shatsky, R., Helsten, T. L., Forero-Torres, A., Liu, M. C., Brown-Swigart, L., Petricoin, E. F., Wulfkuhle, J. D., Asare, S. M., Wilson, A., Singhrao, R., Sit, L., Hirst, G. L., Berry, S., Sanil, A., Asare, A. L., Matthews, J. B., Perlmutter, J., Melisko, M., Rugo, H. S., Schwab, R. B., Symmans, W. F., Yee, D., Van't Veer, L. J., Hylton, N. M., DeMichele, A. M., Berry, D. A., & Esserman, L. J. (2021). Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial. Cancer cell, 39(7), 989-998.e5. https://doi.org/10.1016/j.ccell.2021.05.009
Pusztai, Lajos, et al. "Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial." Cancer cell vol. 39,7 (2021): 989-998.e5. doi: https://doi.org/10.1016/j.ccell.2021.05.009
Pusztai L, Yau C, Wolf DM, Han HS, Du L, Wallace AM, String-Reasor E, Boughey JC, Chien AJ, Elias AD, Beckwith H, Nanda R, Albain KS, Clark AS, Kemmer K, Kalinsky K, Isaacs C, Thomas A, Shatsky R, Helsten TL, Forero-Torres A, Liu MC, Brown-Swigart L, Petricoin EF, Wulfkuhle JD, Asare SM, Wilson A, Singhrao R, Sit L, Hirst GL, Berry S, Sanil A, Asare AL, Matthews JB, Perlmutter J, Melisko M, Rugo HS, Schwab RB, Symmans WF, Yee D, Van't Veer LJ, Hylton NM, DeMichele AM, Berry DA, Esserman LJ. Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial. Cancer Cell. 2021 Jul 12;39(7):989-998.e5. doi: 10.1016/j.ccell.2021.05.009. Epub 2021 Jun 17. PMID: 34143979.
Copy Download .nbib Format: NLM
Identification and characterization of mkk genes and their expression profiles in rainbow trout (Oncorhynchus mykiss) symptomatically or asymptomatically infected with Vibrio anguillarum.

Fish & shellfish immunology

Yang XD, Hou ZS, Liu MQ, Zeng C, Zhao HK, Xin YR, Xiang KW, Yang Q, Wen HS, Li JF.
PMID: 34974153
Fish Shellfish Immunol. 2021 Dec 31;121:1-11. doi: 10.1016/j.fsi.2021.12.049. Epub 2021 Dec 31.

Mitogen-activated protein kinase kinases (MKKs) are intermediate kinases of mitogen-activated protein kinases (MAPKs) signaling pathways. MKKs are activated by mitogen-activated protein kinase kinase kinase (MKKK) and then the activated MKKs trigger the activation of downstream MAPKs. MAPK signaling pathways...

Cite
Yang XD, Hou ZS, Liu MQ, et al. Identification and characterization of mkk genes and their expression profiles in rainbow trout (Oncorhynchus mykiss) symptomatically or asymptomatically infected with Vibrio anguillarum. Fish Shellfish Immunol. 2021;121:1-11doi: 10.1016/j.fsi.2021.12.049.
Yang, X. D., Hou, Z. S., Liu, M. Q., Zeng, C., Zhao, H. K., Xin, Y. R., Xiang, K. W., Yang, Q., Wen, H. S., & Li, J. F. (2021). Identification and characterization of mkk genes and their expression profiles in rainbow trout (Oncorhynchus mykiss) symptomatically or asymptomatically infected with Vibrio anguillarum. Fish & shellfish immunology, 1211-11. https://doi.org/10.1016/j.fsi.2021.12.049
Yang, Xiao-Dong, et al. "Identification and characterization of mkk genes and their expression profiles in rainbow trout (Oncorhynchus mykiss) symptomatically or asymptomatically infected with Vibrio anguillarum." Fish & shellfish immunology vol. 121 (2021): 1-11. doi: https://doi.org/10.1016/j.fsi.2021.12.049
Yang XD, Hou ZS, Liu MQ, Zeng C, Zhao HK, Xin YR, Xiang KW, Yang Q, Wen HS, Li JF. Identification and characterization of mkk genes and their expression profiles in rainbow trout (Oncorhynchus mykiss) symptomatically or asymptomatically infected with Vibrio anguillarum. Fish Shellfish Immunol. 2021 Dec 31;121:1-11. doi: 10.1016/j.fsi.2021.12.049. Epub 2021 Dec 31. PMID: 34974153.
Copy Download .nbib Format: NLM
Cholecystokinin-like peptide mediates satiety by inhibiting sugar attraction.

PLoS genetics

Guo D, Zhang YJ, Zhang S, Li J, Guo C, Pan YF, Zhang N, Liu CX, Jia YL, Li CY, Ma JY, Nässel DR, Gao CF, Wu SF.
PMID: 34398892
PLoS Genet. 2021 Aug 16;17(8):e1009724. doi: 10.1371/journal.pgen.1009724. eCollection 2021 Aug.

Feeding is essential for animal survival and reproduction and is regulated by both internal states and external stimuli. However, little is known about how internal states influence the perception of external sensory cues that regulate feeding behavior. Here, we...

Cite
Guo D, Zhang YJ, Zhang S, et al. Cholecystokinin-like peptide mediates satiety by inhibiting sugar attraction. PLoS Genet. 2021;17(8):e1009724doi: 10.1371/journal.pgen.1009724.
Guo, D., Zhang, Y. J., Zhang, S., Li, J., Guo, C., Pan, Y. F., Zhang, N., Liu, C. X., Jia, Y. L., Li, C. Y., Ma, J. Y., Nässel, D. R., Gao, C. F., & Wu, S. F. (2021). Cholecystokinin-like peptide mediates satiety by inhibiting sugar attraction. PLoS genetics, 17(8), e1009724. https://doi.org/10.1371/journal.pgen.1009724
Guo, Di, et al. "Cholecystokinin-like peptide mediates satiety by inhibiting sugar attraction." PLoS genetics vol. 17,8 (2021): e1009724. doi: https://doi.org/10.1371/journal.pgen.1009724
Guo D, Zhang YJ, Zhang S, Li J, Guo C, Pan YF, Zhang N, Liu CX, Jia YL, Li CY, Ma JY, Nässel DR, Gao CF, Wu SF. Cholecystokinin-like peptide mediates satiety by inhibiting sugar attraction. PLoS Genet. 2021 Aug 16;17(8):e1009724. doi: 10.1371/journal.pgen.1009724. eCollection 2021 Aug. PMID: 34398892; PMCID: PMC8366971.
Copy Download .nbib Format: NLM
EGFR mutation mediates resistance to EGFR tyrosine kinase inhibitors in NSCLC: From molecular mechanisms to clinical research.

Pharmacological research

Dong RF, Zhu ML, Liu MM, Xu YT, Yuan LL, Bian J, Xia YZ, Kong LY.
PMID: 33775864
Pharmacol Res. 2021 May;167:105583. doi: 10.1016/j.phrs.2021.105583. Epub 2021 Mar 26.

With the development of precision medicine, molecular targeted therapy has been widely used in the field of cancer, especially in non-small-cell lung cancer (NSCLC). Epidermal growth factor receptor (EGFR) is a well-recognized and effective target for NSCLC therapies, targeted...

Cite
Dong RF, Zhu ML, Liu MM, et al. EGFR mutation mediates resistance to EGFR tyrosine kinase inhibitors in NSCLC: From molecular mechanisms to clinical research. Pharmacol Res. 2021;167:105583doi: 10.1016/j.phrs.2021.105583.
Dong, R. F., Zhu, M. L., Liu, M. M., Xu, Y. T., Yuan, L. L., Bian, J., Xia, Y. Z., & Kong, L. Y. (2021). EGFR mutation mediates resistance to EGFR tyrosine kinase inhibitors in NSCLC: From molecular mechanisms to clinical research. Pharmacological research, 167105583. https://doi.org/10.1016/j.phrs.2021.105583
Dong, Rui-Fang, et al. "EGFR mutation mediates resistance to EGFR tyrosine kinase inhibitors in NSCLC: From molecular mechanisms to clinical research." Pharmacological research vol. 167 (2021): 105583. doi: https://doi.org/10.1016/j.phrs.2021.105583
Dong RF, Zhu ML, Liu MM, Xu YT, Yuan LL, Bian J, Xia YZ, Kong LY. EGFR mutation mediates resistance to EGFR tyrosine kinase inhibitors in NSCLC: From molecular mechanisms to clinical research. Pharmacol Res. 2021 May;167:105583. doi: 10.1016/j.phrs.2021.105583. Epub 2021 Mar 26. PMID: 33775864.
Copy Download .nbib Format: NLM
Harnessing in situ glutathione for effective ROS generation and tumor suppression via nanohybrid-mediated catabolism dynamic therapy.

Biomaterials

Peng SY, Liu XH, Chen QW, Yu YJ, Liu MD, Zhang XZ.
PMID: 34979416
Biomaterials. 2021 Dec 30;281:121358. doi: 10.1016/j.biomaterials.2021.121358. Epub 2021 Dec 30.

The overexpression of glutathione (GSH) in cancer cells has long been regarded as the primary obstacle for reactive oxygen species (ROS)-involved anti-tumor therapies. To solve this issue, a ferric ion and selenite-codoped calcium phosphate (Fe/Se-CaP) nanohybrid here is fabricated...

Cite
Peng SY, Liu XH, Chen QW, et al. Harnessing in situ glutathione for effective ROS generation and tumor suppression via nanohybrid-mediated catabolism dynamic therapy. Biomaterials. 2021;281:121358doi: 10.1016/j.biomaterials.2021.121358.
Peng, S. Y., Liu, X. H., Chen, Q. W., Yu, Y. J., Liu, M. D., & Zhang, X. Z. (2021). Harnessing in situ glutathione for effective ROS generation and tumor suppression via nanohybrid-mediated catabolism dynamic therapy. Biomaterials, 281121358. https://doi.org/10.1016/j.biomaterials.2021.121358
Peng, Si-Yuan, et al. "Harnessing in situ glutathione for effective ROS generation and tumor suppression via nanohybrid-mediated catabolism dynamic therapy." Biomaterials vol. 281 (2021): 121358. doi: https://doi.org/10.1016/j.biomaterials.2021.121358
Peng SY, Liu XH, Chen QW, Yu YJ, Liu MD, Zhang XZ. Harnessing in situ glutathione for effective ROS generation and tumor suppression via nanohybrid-mediated catabolism dynamic therapy. Biomaterials. 2021 Dec 30;281:121358. doi: 10.1016/j.biomaterials.2021.121358. Epub 2021 Dec 30. PMID: 34979416.
Copy Download .nbib Format: NLM
Hospital-specific Template Matching for Benchmarking Performance in a Diverse Multihospital System.

Medical care

Vincent BM, Molling D, Escobar GJ, Hofer TP, Iwashyna TJ, Liu VX, Rosen AK, Ryan AM, Seelye S, Wiitala WL, Prescott HC.
PMID: 34629424
Med Care. 2021 Dec 01;59(12):1090-1098. doi: 10.1097/MLR.0000000000001645.

BACKGROUND: Hospital-specific template matching is a newer method of hospital performance measurement that may be fairer than regression-based benchmarking. However, it has been tested in only limited research settings.OBJECTIVE: The objective of this study was to test the feasibility...

Cite
Vincent BM, Molling D, Escobar GJ, et al. Hospital-specific Template Matching for Benchmarking Performance in a Diverse Multihospital System. Med Care. 2021;59(12):1090-1098doi: 10.1097/MLR.0000000000001645.
Vincent, B. M., Molling, D., Escobar, G. J., Hofer, T. P., Iwashyna, T. J., Liu, V. X., Rosen, A. K., Ryan, A. M., Seelye, S., Wiitala, W. L., & Prescott, H. C. (2021). Hospital-specific Template Matching for Benchmarking Performance in a Diverse Multihospital System. Medical care, 59(12), 1090-1098. https://doi.org/10.1097/MLR.0000000000001645
Vincent, Brenda M, et al. "Hospital-specific Template Matching for Benchmarking Performance in a Diverse Multihospital System." Medical care vol. 59,12 (2021): 1090-1098. doi: https://doi.org/10.1097/MLR.0000000000001645
Vincent BM, Molling D, Escobar GJ, Hofer TP, Iwashyna TJ, Liu VX, Rosen AK, Ryan AM, Seelye S, Wiitala WL, Prescott HC. Hospital-specific Template Matching for Benchmarking Performance in a Diverse Multihospital System. Med Care. 2021 Dec 01;59(12):1090-1098. doi: 10.1097/MLR.0000000000001645. PMID: 34629424.
Copy Download .nbib Format: NLM
The study of schizogenous formation of secretory ducts in Ferula ferulaeoides (Steud.) Korov.

Protoplasma

Liu MM, Zhao YY, Ma Y, Liu SS, Yao JQ, Chi YP, Li HF, Liao K, Zhu Y.
PMID: 34338853
Protoplasma. 2021 Aug 02; doi: 10.1007/s00709-021-01690-6. Epub 2021 Aug 02.

The secretory ducts of Ferula ferulaeoides (Steud.) Korov. are the main tissue of synthesis, secretion, and accumulation of resin. The formation of secretory ducts is closely related to the harvest and quality of resin, but the lumen formation mode...

Cite
Liu MM, Zhao YY, Ma Y, et al. The study of schizogenous formation of secretory ducts in Ferula ferulaeoides (Steud.) Korov. Protoplasma. 2021;doi: 10.1007/s00709-021-01690-6.
Liu, M. M., Zhao, Y. Y., Ma, Y., Liu, S. S., Yao, J. Q., Chi, Y. P., Li, H. F., Liao, K., & Zhu, Y. (2021). The study of schizogenous formation of secretory ducts in Ferula ferulaeoides (Steud.) Korov. Protoplasma, . https://doi.org/10.1007/s00709-021-01690-6
Liu, Meng-Meng, et al. "The study of schizogenous formation of secretory ducts in Ferula ferulaeoides (Steud.) Korov." Protoplasma vol. (2021). doi: https://doi.org/10.1007/s00709-021-01690-6
Liu MM, Zhao YY, Ma Y, Liu SS, Yao JQ, Chi YP, Li HF, Liao K, Zhu Y. The study of schizogenous formation of secretory ducts in Ferula ferulaeoides (Steud.) Korov. Protoplasma. 2021 Aug 02; doi: 10.1007/s00709-021-01690-6. Epub 2021 Aug 02. PMID: 34338853.
Copy Download .nbib Format: NLM
Observation on the Clinical Effect of Apatinib Combined with Chemotherapy in the Treatment of Advanced Non-Small Cell Lung Cancer.

Pakistan journal of medical sciences

Cui YJ, Liu J, Liu MM, Zhang HZ.
PMID: 34290779
Pak J Med Sci. 2021 Jul-Aug;37(4):1036-1041. doi: 10.12669/pjms.37.4.4066.

OBJECTIVES: To evaluate the clinical effect of apatinib combined with chemotherapy in the treatment of advanced non-small cell lung cancer (NSCLC).METHODS: Eighty patients with advanced NSCLC treated in Hebei General Hospital from January 2017 to July 2020 were randomly...

Cite
Cui YJ, Liu J, Liu MM, et al. Observation on the Clinical Effect of Apatinib Combined with Chemotherapy in the Treatment of Advanced Non-Small Cell Lung Cancer. Pak J Med Sci. 2021;37(4):1036-1041doi: 10.12669/pjms.37.4.4066.
Cui, Y. J., Liu, J., Liu, M. M., & Zhang, H. Z. (2021). Observation on the Clinical Effect of Apatinib Combined with Chemotherapy in the Treatment of Advanced Non-Small Cell Lung Cancer. Pakistan journal of medical sciences, 37(4), 1036-1041. https://doi.org/10.12669/pjms.37.4.4066
Cui, Yu-Jie, et al. "Observation on the Clinical Effect of Apatinib Combined with Chemotherapy in the Treatment of Advanced Non-Small Cell Lung Cancer." Pakistan journal of medical sciences vol. 37,4 (2021): 1036-1041. doi: https://doi.org/10.12669/pjms.37.4.4066
Cui YJ, Liu J, Liu MM, Zhang HZ. Observation on the Clinical Effect of Apatinib Combined with Chemotherapy in the Treatment of Advanced Non-Small Cell Lung Cancer. Pak J Med Sci. 2021 Jul-Aug;37(4):1036-1041. doi: 10.12669/pjms.37.4.4066. PMID: 34290779; PMCID: PMC8281184.
Copy Download .nbib Format: NLM
RASAL2 Confers Collateral MEK/EGFR Dependency in Chemoresistant Triple-Negative Breast Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research

Koh SB, Ross K, Isakoff SJ, Melkonjan N, He L, Matissek KJ, Schultz A, Mayer EL, Traina TA, Carey LA, Rugo HS, Liu MC, Stearns V, Langenbucher A, Saladi SV, Ramaswamy S, Lawrence MS, Ellisen LW.
PMID: 34168046
Clin Cancer Res. 2021 Sep 01;27(17):4883-4897. doi: 10.1158/1078-0432.CCR-21-0714. Epub 2021 Jun 24.

PURPOSE: While chemotherapy remains the standard treatment for triple-negative breast cancer (TNBC), identifying and managing chemoresistant tumors has proven elusive. We sought to discover hallmarks and therapeutically actionable features of refractory TNBC through molecular analysis of primary chemoresistant TNBC...

Cite
Koh SB, Ross K, Isakoff SJ, et al. RASAL2 Confers Collateral MEK/EGFR Dependency in Chemoresistant Triple-Negative Breast Cancer. Clin Cancer Res. 2021;27(17):4883-4897doi: 10.1158/1078-0432.CCR-21-0714.
Koh, S. B., Ross, K., Isakoff, S. J., Melkonjan, N., He, L., Matissek, K. J., Schultz, A., Mayer, E. L., Traina, T. A., Carey, L. A., Rugo, H. S., Liu, M. C., Stearns, V., Langenbucher, A., Saladi, S. V., Ramaswamy, S., Lawrence, M. S., & Ellisen, L. W. (2021). RASAL2 Confers Collateral MEK/EGFR Dependency in Chemoresistant Triple-Negative Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 27(17), 4883-4897. https://doi.org/10.1158/1078-0432.CCR-21-0714
Koh, Siang-Boon, et al. "RASAL2 Confers Collateral MEK/EGFR Dependency in Chemoresistant Triple-Negative Breast Cancer." Clinical cancer research : an official journal of the American Association for Cancer Research vol. 27,17 (2021): 4883-4897. doi: https://doi.org/10.1158/1078-0432.CCR-21-0714
Koh SB, Ross K, Isakoff SJ, Melkonjan N, He L, Matissek KJ, Schultz A, Mayer EL, Traina TA, Carey LA, Rugo HS, Liu MC, Stearns V, Langenbucher A, Saladi SV, Ramaswamy S, Lawrence MS, Ellisen LW. RASAL2 Confers Collateral MEK/EGFR Dependency in Chemoresistant Triple-Negative Breast Cancer. Clin Cancer Res. 2021 Sep 01;27(17):4883-4897. doi: 10.1158/1078-0432.CCR-21-0714. Epub 2021 Jun 24. PMID: 34168046; PMCID: PMC8416935.
Copy Download .nbib Format: NLM
CircFOXM1 silencing represses cell proliferation, migration and invasion by regulating miR-515-5p/ADAM10 axis in prostate cancer.

Anti-cancer drugs

Liu GX, Zheng T, Zhang Y, Hao P.
PMID: 34387599
Anticancer Drugs. 2022 Jan 01;33(1):e573-e583. doi: 10.1097/CAD.0000000000001183.

Circular FOXM1 (circFOXM1) has been demonstrated to participate in the initiation and development of cancers, including prostate cancer (PCa). However, there is no relevant information on the regulation of PCa by circFOXM1. The RNA level of circFOXM1 was detected...

Cite
Liu GX, Zheng T, Zhang Y, et al. CircFOXM1 silencing represses cell proliferation, migration and invasion by regulating miR-515-5p/ADAM10 axis in prostate cancer. Anticancer Drugs. 2022;33(1):e573-e583doi: 10.1097/CAD.0000000000001183.
Liu, G. X., Zheng, T., Zhang, Y., & Hao, P. (2022). CircFOXM1 silencing represses cell proliferation, migration and invasion by regulating miR-515-5p/ADAM10 axis in prostate cancer. Anti-cancer drugs, 33(1), e573-e583. https://doi.org/10.1097/CAD.0000000000001183
Liu, Gong-Xue, et al. "CircFOXM1 silencing represses cell proliferation, migration and invasion by regulating miR-515-5p/ADAM10 axis in prostate cancer." Anti-cancer drugs vol. 33,1 (2022): e573-e583. doi: https://doi.org/10.1097/CAD.0000000000001183
Liu GX, Zheng T, Zhang Y, Hao P. CircFOXM1 silencing represses cell proliferation, migration and invasion by regulating miR-515-5p/ADAM10 axis in prostate cancer. Anticancer Drugs. 2022 Jan 01;33(1):e573-e583. doi: 10.1097/CAD.0000000000001183. PMID: 34387599.
Copy Download .nbib Format: NLM
Ice needles weave patterns of stones in freezing landscapes.

Proceedings of the National Academy of Sciences of the United States of America

Li A, Matsuoka N, Niu F, Chen J, Ge Z, Hu W, Li D, Hallet B, van de Koppel J, Goldenfeld N, Liu QX.
PMID: 34593647
Proc Natl Acad Sci U S A. 2021 Oct 05;118(40). doi: 10.1073/pnas.2110670118. Epub 2021 Sep 30.

Patterned ground, defined by the segregation of stones in soil according to size, is one of the most strikingly self-organized characteristics of polar and high-alpine landscapes. The presence of such patterns on Mars has been proposed as evidence for...

Cite
Li A, Matsuoka N, Niu F, et al. Ice needles weave patterns of stones in freezing landscapes. Proc Natl Acad Sci U S A. 2021;118(40)doi: 10.1073/pnas.2110670118.
Li, A., Matsuoka, N., Niu, F., Chen, J., Ge, Z., Hu, W., Li, D., Hallet, B., van de Koppel, J., Goldenfeld, N., & Liu, Q. X. (2021). Ice needles weave patterns of stones in freezing landscapes. Proceedings of the National Academy of Sciences of the United States of America, 118(40), . https://doi.org/10.1073/pnas.2110670118
Li, Anyuan, et al. "Ice needles weave patterns of stones in freezing landscapes." Proceedings of the National Academy of Sciences of the United States of America vol. 118,40 (2021). doi: https://doi.org/10.1073/pnas.2110670118
Li A, Matsuoka N, Niu F, Chen J, Ge Z, Hu W, Li D, Hallet B, van de Koppel J, Goldenfeld N, Liu QX. Ice needles weave patterns of stones in freezing landscapes. Proc Natl Acad Sci U S A. 2021 Oct 05;118(40). doi: 10.1073/pnas.2110670118. Epub 2021 Sep 30. PMID: 34593647; PMCID: PMC8501760.
Copy Download .nbib Format: NLM
Okicamelliaside targets the N-terminal chaperone pocket of HSP90 disrupts the chaperone protein interaction of HSP90-CDC37 and exerts antitumor activity.

Acta pharmacologica Sinica

Cheng CJ, Liu KX, Zhang M, Shen FK, Ye LL, Wu WB, Hou XT, Hao EW, Hou YY, Bai G.
PMID: 34326484
Acta Pharmacol Sin. 2021 Jul 29; doi: 10.1038/s41401-021-00737-x. Epub 2021 Jul 29.

Heat shock protein 90 (HSP90) has been recognized as a crucial target in cancer cells. However, various toxic reactions targeting the ATP binding site of HSP90 may not be the best choice for HSP90 inhibitors. In this paper, an...

Cite
Cheng CJ, Liu KX, Zhang M, et al. Okicamelliaside targets the N-terminal chaperone pocket of HSP90 disrupts the chaperone protein interaction of HSP90-CDC37 and exerts antitumor activity. Acta Pharmacol Sin. 2021;doi: 10.1038/s41401-021-00737-x.
Cheng, C. J., Liu, K. X., Zhang, M., Shen, F. K., Ye, L. L., Wu, W. B., Hou, X. T., Hao, E. W., Hou, Y. Y., & Bai, G. (2021). Okicamelliaside targets the N-terminal chaperone pocket of HSP90 disrupts the chaperone protein interaction of HSP90-CDC37 and exerts antitumor activity. Acta pharmacologica Sinica, . https://doi.org/10.1038/s41401-021-00737-x
Cheng, Chuan-Jing, et al. "Okicamelliaside targets the N-terminal chaperone pocket of HSP90 disrupts the chaperone protein interaction of HSP90-CDC37 and exerts antitumor activity." Acta pharmacologica Sinica vol. (2021). doi: https://doi.org/10.1038/s41401-021-00737-x
Cheng CJ, Liu KX, Zhang M, Shen FK, Ye LL, Wu WB, Hou XT, Hao EW, Hou YY, Bai G. Okicamelliaside targets the N-terminal chaperone pocket of HSP90 disrupts the chaperone protein interaction of HSP90-CDC37 and exerts antitumor activity. Acta Pharmacol Sin. 2021 Jul 29; doi: 10.1038/s41401-021-00737-x. Epub 2021 Jul 29. PMID: 34326484.
Copy Download .nbib Format: NLM
Showing 337 to 348 of 3217 entries